Literature DB >> 30138914

Short-Chain Fatty Acids Manifest Stimulative and Protective Effects on Intestinal Barrier Function Through the Inhibition of NLRP3 Inflammasome and Autophagy.

Yanhai Feng1, Yu Wang2, Pei Wang1, Yalan Huang3, Fengjun Wang1.   

Abstract

BACKGROUND/AIMS: Short-chain fatty acids (SCFAs) are the major energy resources of intestinal epithelial cells. It has been reported that SCFAs can repair the dysfunction of intestinal barrier, however, the underlying mechanisms are still not fully understood. Here, we investigated the stimulative and protective effects of SCFAs on intestinal barrier function and the possible mechanisms.
METHODS: To investigate the effects of SCFAs on intestinal barrier function, the Caco-2 monolayers were exposed to acetate, propionate, butyrate respectively or simultaneously without or with lipopolysaccharide (LPS). Next, Caco-2 cells were treated with trichostatin A and etomoxir to identify whether SCFAs act as HDAC inhibitors or energy substances. To activate NLRP3 inflammasome and autophagy, Caco-2 cells were treated with LPS+ATP and rapamycin respectively without or with SCFAs. The transepithelial electrical resistance (TER) and paracellular permeability were respectively detected with a Millicell-ERS voltohmmeter and fluorescein isothiocyanate-labeled dextran. Immunoblotting and immunofluorescence were applied to analyze the expression and distribution of tight junction proteins, and the activation of NLRP3 inflammasome and autophagy.
RESULTS: Acetate (0.5mM), propionate(0.01mM) and butyrate (0.01mM) alone or in combination significantly increased TER, and stimulated the formation of tight junction. SCFAs also dramatically attenuated the LPS-induced TER reduction and paracellular permeability increase, accompanying significantly alleviated morphological disruption of ZO-1 and occludin. Meanwhile, the activation of NLRP3 inflammasome and autophagy induced by LPS were significantly inhibited by SCFAs. Trichostatin A imitated the inhibiting action of SCFAs on NLRP3 inflammasome, whereas etomoxir blocked the action of SCFAs on protecting intestinal barrier and inhibiting autophagy. In addition, the activation of autophagy and NLRP3 inflammasome by rapamycin and LPS+ATP resulted in TER reduction, paracellular permeability increase and morphological disruption of both ZO-1 and occludin, which was alleviated by SCFAs.
CONCLUSION: It is suggested that SCFAs stimulate the formation of intestinal barrier, and protect the intestinal barrier from the disruption of LPS through inhibiting NLRP3 inflammasome and autophagy. In addition, SCFAs act as energy substances to protect intestinal barrier and inhibit autophagy, but act as HDAC inhibitors to suppress NLRP3 inflammasome. Furthermore, the mutual promoting action between NLRP3 inflammasome and autophagy would destroy intestinal barrier function, which could be alleviated by SCFAs.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Autophagy; Intestinal barrier; Lipopolysaccharide; NLRP3 inflammasome; Short-chain fatty acids; Tight junction

Mesh:

Substances:

Year:  2018        PMID: 30138914     DOI: 10.1159/000492853

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  73 in total

1.  PARK2 attenuates house dust mite-induced inflammatory reaction, pyroptosis and barrier dysfunction in BEAS-2B cells by ubiquitinating NLRP3.

Authors:  Xiahui Ge; Feng Cai; Yan Shang; Feng Chi; Hua Xiao; Jing Xu; Youhui Fu; Chong Bai
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

Review 2.  Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease.

Authors:  Marc Y Donath; Daniel T Meier; Marianne Böni-Schnetzler
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

3.  Butyrate ameliorates caerulein-induced acute pancreatitis and associated intestinal injury by tissue-specific mechanisms.

Authors:  Xiaohua Pan; Xin Fang; Fei Wang; Hongli Li; Wenying Niu; Wenjie Liang; Chengfei Wu; Jiahong Li; Xing Tu; Li-Long Pan; Jia Sun
Journal:  Br J Pharmacol       Date:  2019-12-08       Impact factor: 8.739

4.  NLRP3 inflammasome as a novel therapeutic target for heart failure.

Authors:  Shuangcui Wang; Jiaqi Zhang; Yuli Wang; Xijuan Jiang; Maojuan Guo; Zhen Yang
Journal:  Anatol J Cardiol       Date:  2022-01       Impact factor: 1.596

5.  ASCs derived from burn patients are more prone to increased oxidative metabolism and reactive oxygen species upon passaging.

Authors:  David M Burmeister; Grace Chu-Yuan Chu; Tony Chao; Tiffany C Heard; Belinda I Gómez; Linda E Sousse; Shanmugasundaram Natesan; Robert J Christy
Journal:  Stem Cell Res Ther       Date:  2021-05-06       Impact factor: 6.832

Review 6.  Intestinal Barrier and Permeability in Health, Obesity and NAFLD.

Authors:  Piero Portincasa; Leonilde Bonfrate; Mohamad Khalil; Maria De Angelis; Francesco Maria Calabrese; Mauro D'Amato; David Q-H Wang; Agostino Di Ciaula
Journal:  Biomedicines       Date:  2021-12-31

7.  Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans.

Authors:  Alessio Basolo; Maximilian Hohenadel; Qi Yan Ang; Paolo Piaggi; Sascha Heinitz; Mary Walter; Peter Walter; Shannon Parrington; Donovan D Trinidad; Reiner Jumpertz von Schwartzenberg; Peter J Turnbaugh; Jonathan Krakoff
Journal:  Nat Med       Date:  2020-03-23       Impact factor: 53.440

8.  Butyrate Alleviates Cytokine-Induced Barrier Dysfunction by Modifying Claudin-2 Levels.

Authors:  Xinyi Huang; Tadayuki Oshima; Toshihiko Tomita; Hirokazu Fukui; Hiroto Miwa
Journal:  Biology (Basel)       Date:  2021-03-09

Review 9.  Consideration of Gut Microbiome in Murine Models of Diseases.

Authors:  Chunye Zhang; Craig L Franklin; Aaron C Ericsson
Journal:  Microorganisms       Date:  2021-05-14

10.  Maturation of the preterm gastrointestinal tract can be defined by host and microbial markers for digestion and barrier defense.

Authors:  Jannie G E Henderickx; Romy D Zwittink; Ingrid B Renes; Richard A van Lingen; Diny van Zoeren-Grobben; Liesbeth J Groot Jebbink; Sjef Boeren; Ruurd M van Elburg; Jan Knol; Clara Belzer
Journal:  Sci Rep       Date:  2021-06-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.